Biogerontology · 2025 · Cell study · PMID 40908429
Explore the library
Preclinical evidenceSynthetic AEDG tetrapeptide
Epitalon
Epitalon, also spelled epithalon, is a synthetic four-amino-acid peptide with the sequence AEDG. It is discussed in pineal-related, telomere and aging research, without an established human longevity benefit.
Also indexed as: Epithalon · AEDG tetrapeptide
A clear starting point
Epitalon, also spelled epithalon, is a synthetic four-amino-acid peptide with the sequence AEDG. It is discussed in pineal-related, telomere and aging research, without an established human longevity benefit.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Telomere / cellular senescence
Epitalon, also spelled epithalon, is a synthetic four-amino-acid peptide with the sequence AEDG. It is discussed in pineal-related, telomere and aging research, without an established human longevity benefit.
- Targets & processes
- Telomere / cellular senescence
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Telomerase, telomere maintenance and pineal-related biology.
What this does not establish
The linked 2025 study is in human cell lines, including cancer cells—not a human clinical trial or evidence of longer lifespan.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Long-term safety is unknown. Telomere effects in cancer cell lines are not evidence of cancer treatment or safety. FDA identifies immunogenicity and insufficient safety information.
Contraindications & cautions
Not an exhaustive contraindication review. Long-term safety is unknown. Telomere effects in cancer cell lines are not evidence of cancer treatment or safety. FDA identifies immunogenicity and insufficient safety information.
Medication & supplement interactions
Interaction information is incomplete. Long-term safety is unknown. Telomere effects in cancer cell lines are not evidence of cancer treatment or safety. FDA identifies immunogenicity and insufficient safety information.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.